We found that SOX2 is expressed in 28% of an array of 88 sarcoma patients, being UPS, synovial sarcomas and Ewing sarcomas those presenting a higher percentage of positive cases in concordance with the results of previous reports [43,44]. Here, SOX2 is linked to sarcoma.